TrialA Study of Buntanetap in Participants With PD
Trial details
- Registry ID
- NCT07284784
- Phase
- Phase 2, Phase 3
Drug research
buntanetap/posiphen
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as ANVS401; Posiphen Tartrate
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Buntanetap in Participants With PDNCT07284784 | ANVS | Phase 2, Phase 3 | Recruiting | 2029-09Estimated |
| A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PDNCT05357989 | ANVS | Phase 3 | Completed | 2023-12-04Actual |
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early ADNCT06709014 | ANVS | Phase 3 | Active not recruiting | 2027-12Estimated |
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
Trial details
- Registry ID
- NCT05357989
- Phase
- Phase 3
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
Trial details
- Registry ID
- NCT06709014
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |